Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy.

ABSTRACT:

Aims

Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAbs) are recommended for high-risk patients if the low-density lipoprotein cholesterol targets are not achieved with statins and ezetimibe. We studied persistence and adherence to (i) PCSK9 mAbs and (ii) statins and ezetimibe in a nationwide cohort of incident PCSK9 mAb users.

Methods and results

Information on all PCSK9 mAb users ≤80 years from 2015 through 2023 were extracted from the Norwegian Drug Registry. Discontinuation was defined as a gap in treatment ≥180 days and ≥90 days. Adherence was measured as the proportion of days covered during the initial year of PCSK9 mAb therapy. We analysed adherence of statins and ezetimibe before and after PCSK9 mAb initiation. Of 4784 patients initiatin

SUBMITTER: Engebretsen I 

PROVIDER: S-EPMC12714381 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature